Cargando…

KIR3DS1/HLA-B Bw4-80Ile Genotype Is Correlated with the IFN-α Therapy Response in hepatitis B e antigen-Positive Chronic Hepatitis B

To date, several on-treatment-level virological and serological indices that may predict the response to interferon alpha (IFN-α) have been reported. However, no effective predictors, such as drug–response genes, that can be detected before administration of anti-hepatitis B virus (HBV) therapy with...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wenting, Shen, Xiaokun, Fu, Binqing, Guo, Chuang, Liu, Yanyan, Ye, Ying, Sun, Rui, Li, Jiabin, Tian, Zhigang, Wei, Haiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641573/
https://www.ncbi.nlm.nih.gov/pubmed/29075265
http://dx.doi.org/10.3389/fimmu.2017.01285
_version_ 1783271250601181184
author Li, Wenting
Shen, Xiaokun
Fu, Binqing
Guo, Chuang
Liu, Yanyan
Ye, Ying
Sun, Rui
Li, Jiabin
Tian, Zhigang
Wei, Haiming
author_facet Li, Wenting
Shen, Xiaokun
Fu, Binqing
Guo, Chuang
Liu, Yanyan
Ye, Ying
Sun, Rui
Li, Jiabin
Tian, Zhigang
Wei, Haiming
author_sort Li, Wenting
collection PubMed
description To date, several on-treatment-level virological and serological indices that may predict the response to interferon alpha (IFN-α) have been reported. However, no effective predictors, such as drug–response genes, that can be detected before administration of anti-hepatitis B virus (HBV) therapy with IFN-α, have been found. In the diverse range of chronic viral infection, genes that affect human immunity play important roles in understanding host and viral co-evolution. Killer-cell immunoglobulin-like receptors (KIRs), which are highly polymorphic at the allele and haplotype levels, participate in the antiviral function of natural killer (NK) cells via fine-tuning inhibition and activation of NK-cell responses that occur when the NK cells interact with human leukocyte antigen (HLA) class I molecules on target cells. For each individual, the pairing of KIR and HLA ligand is genetically determined. To investigate whether a particular KIR and HLA repertoire influences the risk of HBV infection and response to IFN-α treatment for chronic hepatitis B (CHB), we genotyped the KIRs and HLA ligands of 119 hepatitis B e antigen (HBeAg)-positive CHB patients. These patients included 43 patients who achieved sustained response (SR) induced by IFN-α treatment for 48 weeks, 76 patients who achieved no response (NR), and 96 healthy subjects as controls. SR was defined as HBeAg loss with HBV DNA < 2,000 IU/ml and alanine aminotransferase normalization at 24 weeks posttreatment (week 72). In this study, we showed that activating KIR genes were less prevalent in Han Chinese, especially in Han Chinese with CHB, than in Caucasians. Furthermore, the KIR3DS1 gene, in combination with HLA-B Bw4-80Ile, strongly influenced the therapeutic outcomes for CHB patients who were treated with IFN-α. The frequency of the combination of genes encoding KIR3DS1 and HLA-B Bw4-80Ile was higher in patients who had a sustained treatment response than in patients who had NR [35.3 versus 1.3%; odds ratio (OR) = 19.85; P = 0.0008]. Activating KIR3DS1 and HLA-B Bw4-80Ile synergistically predicted SR to IFN-α for HBeAg-positive CHB patients. Genotyping for the KIR3DS1 gene and the HLA-B Bw4-80Ile allele might help physicians choose the optimal candidates for anti-HBV treatment with IFN-α.
format Online
Article
Text
id pubmed-5641573
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-56415732017-10-26 KIR3DS1/HLA-B Bw4-80Ile Genotype Is Correlated with the IFN-α Therapy Response in hepatitis B e antigen-Positive Chronic Hepatitis B Li, Wenting Shen, Xiaokun Fu, Binqing Guo, Chuang Liu, Yanyan Ye, Ying Sun, Rui Li, Jiabin Tian, Zhigang Wei, Haiming Front Immunol Immunology To date, several on-treatment-level virological and serological indices that may predict the response to interferon alpha (IFN-α) have been reported. However, no effective predictors, such as drug–response genes, that can be detected before administration of anti-hepatitis B virus (HBV) therapy with IFN-α, have been found. In the diverse range of chronic viral infection, genes that affect human immunity play important roles in understanding host and viral co-evolution. Killer-cell immunoglobulin-like receptors (KIRs), which are highly polymorphic at the allele and haplotype levels, participate in the antiviral function of natural killer (NK) cells via fine-tuning inhibition and activation of NK-cell responses that occur when the NK cells interact with human leukocyte antigen (HLA) class I molecules on target cells. For each individual, the pairing of KIR and HLA ligand is genetically determined. To investigate whether a particular KIR and HLA repertoire influences the risk of HBV infection and response to IFN-α treatment for chronic hepatitis B (CHB), we genotyped the KIRs and HLA ligands of 119 hepatitis B e antigen (HBeAg)-positive CHB patients. These patients included 43 patients who achieved sustained response (SR) induced by IFN-α treatment for 48 weeks, 76 patients who achieved no response (NR), and 96 healthy subjects as controls. SR was defined as HBeAg loss with HBV DNA < 2,000 IU/ml and alanine aminotransferase normalization at 24 weeks posttreatment (week 72). In this study, we showed that activating KIR genes were less prevalent in Han Chinese, especially in Han Chinese with CHB, than in Caucasians. Furthermore, the KIR3DS1 gene, in combination with HLA-B Bw4-80Ile, strongly influenced the therapeutic outcomes for CHB patients who were treated with IFN-α. The frequency of the combination of genes encoding KIR3DS1 and HLA-B Bw4-80Ile was higher in patients who had a sustained treatment response than in patients who had NR [35.3 versus 1.3%; odds ratio (OR) = 19.85; P = 0.0008]. Activating KIR3DS1 and HLA-B Bw4-80Ile synergistically predicted SR to IFN-α for HBeAg-positive CHB patients. Genotyping for the KIR3DS1 gene and the HLA-B Bw4-80Ile allele might help physicians choose the optimal candidates for anti-HBV treatment with IFN-α. Frontiers Media S.A. 2017-10-11 /pmc/articles/PMC5641573/ /pubmed/29075265 http://dx.doi.org/10.3389/fimmu.2017.01285 Text en Copyright © 2017 Li, Shen, Fu, Guo, Liu, Ye, Sun, Li, Tian and Wei. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Li, Wenting
Shen, Xiaokun
Fu, Binqing
Guo, Chuang
Liu, Yanyan
Ye, Ying
Sun, Rui
Li, Jiabin
Tian, Zhigang
Wei, Haiming
KIR3DS1/HLA-B Bw4-80Ile Genotype Is Correlated with the IFN-α Therapy Response in hepatitis B e antigen-Positive Chronic Hepatitis B
title KIR3DS1/HLA-B Bw4-80Ile Genotype Is Correlated with the IFN-α Therapy Response in hepatitis B e antigen-Positive Chronic Hepatitis B
title_full KIR3DS1/HLA-B Bw4-80Ile Genotype Is Correlated with the IFN-α Therapy Response in hepatitis B e antigen-Positive Chronic Hepatitis B
title_fullStr KIR3DS1/HLA-B Bw4-80Ile Genotype Is Correlated with the IFN-α Therapy Response in hepatitis B e antigen-Positive Chronic Hepatitis B
title_full_unstemmed KIR3DS1/HLA-B Bw4-80Ile Genotype Is Correlated with the IFN-α Therapy Response in hepatitis B e antigen-Positive Chronic Hepatitis B
title_short KIR3DS1/HLA-B Bw4-80Ile Genotype Is Correlated with the IFN-α Therapy Response in hepatitis B e antigen-Positive Chronic Hepatitis B
title_sort kir3ds1/hla-b bw4-80ile genotype is correlated with the ifn-α therapy response in hepatitis b e antigen-positive chronic hepatitis b
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641573/
https://www.ncbi.nlm.nih.gov/pubmed/29075265
http://dx.doi.org/10.3389/fimmu.2017.01285
work_keys_str_mv AT liwenting kir3ds1hlabbw480ilegenotypeiscorrelatedwiththeifnatherapyresponseinhepatitisbeantigenpositivechronichepatitisb
AT shenxiaokun kir3ds1hlabbw480ilegenotypeiscorrelatedwiththeifnatherapyresponseinhepatitisbeantigenpositivechronichepatitisb
AT fubinqing kir3ds1hlabbw480ilegenotypeiscorrelatedwiththeifnatherapyresponseinhepatitisbeantigenpositivechronichepatitisb
AT guochuang kir3ds1hlabbw480ilegenotypeiscorrelatedwiththeifnatherapyresponseinhepatitisbeantigenpositivechronichepatitisb
AT liuyanyan kir3ds1hlabbw480ilegenotypeiscorrelatedwiththeifnatherapyresponseinhepatitisbeantigenpositivechronichepatitisb
AT yeying kir3ds1hlabbw480ilegenotypeiscorrelatedwiththeifnatherapyresponseinhepatitisbeantigenpositivechronichepatitisb
AT sunrui kir3ds1hlabbw480ilegenotypeiscorrelatedwiththeifnatherapyresponseinhepatitisbeantigenpositivechronichepatitisb
AT lijiabin kir3ds1hlabbw480ilegenotypeiscorrelatedwiththeifnatherapyresponseinhepatitisbeantigenpositivechronichepatitisb
AT tianzhigang kir3ds1hlabbw480ilegenotypeiscorrelatedwiththeifnatherapyresponseinhepatitisbeantigenpositivechronichepatitisb
AT weihaiming kir3ds1hlabbw480ilegenotypeiscorrelatedwiththeifnatherapyresponseinhepatitisbeantigenpositivechronichepatitisb